Chronic lymphocytic leukemia
Conditions
Brief summary
Primary endpoint Progression-free survival (PFS), defined as the time from randomization to progression or death, a clinically important endpoint.
Detailed description
Secondary endpoints Response to treatment (including MRD), time to next line of treatment. The amount of change in quality of life. Treatment safety based on the assessment of adverse events. Overall survival is defined as the time from randomization to death from any cause.
Interventions
DRUGVenclyxto 50 mg film-coated tablets
DRUGVenclyxto 100 mg film-coated tablets
DRUGVenclyxto 10 mg film-coated tablets
DRUGGazyvaro 1
DRUG000 mg concentrate for solution for infusion.
Sponsors
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint Progression-free survival (PFS), defined as the time from randomization to progression or death, a clinically important endpoint. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints Response to treatment (including MRD), time to next line of treatment. The amount of change in quality of life. Treatment safety based on the assessment of adverse events. Overall survival is defined as the time from randomization to death from any cause. | — |
Countries
Poland
Outcome results
None listed